SV investment has resulted in the approval of 24 novel therapeutics
SV News
12 April 2022Portfolio NewsSV Health Investors Joins Prilenia Series B as the Company Prepares for ALS and HD Data Readouts in the Next 12 Months
10 April 2022SV NewsLife Sciences Summit: venture capital plugs gap in funding- 5 April 2022Portfolio NewsCatamaran Bio Appoints Frank Lee as Chair of its Board of Directors
31 March 2022SV NewsKate Bingham interviewed by Beth Rigby, Sky News, on the lessons learnt from the UK Vaccine Taskforce
30 March 2022SV NewsKate Bingham shared the key lessons learnt from the success of the UK Vaccine Taskforce at The Royal Society’s recent Science of COVID-19 event.
2 March 2022Portfolio NewsRondo Therapeutics Closes $67 Million Series A Financing to Advance Next-Generation Immuno-Oncology Platform for Solid Tumors
22 February 2022Portfolio NewsEyeBio Raises $65M in Series A Funding to Develop New Generation of Eye Disease Therapies
29 November 2021Portfolio NewsQuell Therapeutics Raises $156 million in Oversubscribed Series B Financing to Advance its Pioneering Multi-Modular Engineered T Regulatory (Treg) Cell Therapy Pipeline and Platform
10 November 2021Portfolio NewsSitryx appoints Tanya E. Borsuk, Ph.D., as Chief Business Officer
26 October 2021Portfolio NewsXilio Therapeutics Announces Closing of Initial Public Offering- 21 October 2021Portfolio NewsXilio Therapeutics Announces Pricing of Initial Public Offering
- 18 October 2021Portfolio NewsXilio Therapeutics Announces FDA Clearance of Investigational New Drug Application for XTX202 for the Treatment of Solid Tumors
